T-cell tolerance and autoimmune diabetes

T. D. Brumeanu, C. A. Bona, S. Casares*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Herein we describe the major signaling events that occur in T-cells upon T-cell receptor (TCR) engagement, and the mechanisms responsible for the induction of T-cell anergy that may ultimately lead to the development of immunospecific therapies in T-cell mediated autoimmune diseases. A new type of antigen presenting molecule (dimeric MHC class-II/peptide, DEF) endowed with antigen-specific immunomodulatory effects such as induction of Th2 polarization and T-cell anergy is also described as a potential antidiabetogenic agent. According to our preliminary results, the MHC II/peptide-based approach may provide rational grounds for further development of antigen-specific immunotherapeutic agents such as human-like MHC H/peptide chimeras endowed with efficient down-regulatory effects in CD4 T-cell-mediated autoimmune diseases such as Type I diabetes, multiple sclerosis, primary biliary cirrhosis, and rheumatoid arthritis.

Original languageEnglish
Pages (from-to)301-331
Number of pages31
JournalInternational Reviews of Immunology
Issue number2
StatePublished - 2001
Externally publishedYes


  • Insulin-dependent diabetes mellitus
  • Recombinant MHC II-peptide chimera
  • T-cell tolerance
  • TCR/CD4 signaling


Dive into the research topics of 'T-cell tolerance and autoimmune diabetes'. Together they form a unique fingerprint.

Cite this